Fitbit Inc (NYSE:FIT) shares are up nearly 4% in early Monday trading after Barclays analyst Matt McClintock upgraded the company from Equal Weight to Overweight, while maintaining a price target of $49. The analyst attributes his upgrade to a recent pullback in Fitbit shares. In addition, analyst Erinn Murphy of Piper Jaffray also expressed positive sentiment regarding FitBit, citing an upcoming investor meeting with the company’s CEO and Black Friday data. She states, “We will be hosting investor meetings with the CFO in NY on Tuesday in addition to our Health Care conference on December 2.” The analyst continued, “During Black Friday, while four of the five major SKUs were promoted, we believe this was on plan and our checks suggest levels sold down well. More importantly, Flex (the highest margin SKU by our belief) was full-price throughout the weekend. On Sunday, all pricing moved back to full-price in a disciplined fashion. In London, FIT was not promoted. At John Lewis for example, Fitbit was full-price and Misfit was 65% off and Withings was 25% off.” The analyst maintains an Overweight rating and a price target of $60 on the stock.

According to TipRanks, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, out of the 11 analysts who have rated FitBit in the last 3 months, 9 gave a Buy rating while 2 remain on the sidelines. The average 12-month price target for the stock is $52, marking an 87.5% upside from where shares last closed.FIT Consensus

Horizon Pharma PLC (NASDAQ:HZNPis up nearly one percent this morning after news that the European Commission will approve RAVITI Oral Liquid as an adjunctive therapy for the management of Urea Cycle Disorders in children and adults. The decision allows the company to market its drug in all 28 member states of the EU. Additionally, he Centralized marketing authorization will form the basis for recognition by the Member States of the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein, for the product to be placed on the market.” Preceding this decision is the Positive opinion adopted on September 24th by the Committee for Medicinal Products for Human Use of the European Medicines Agency. CEO Timothy P Walbert states “The approval of RAVICTI in the European Union and the European Economic Area represents a significant milestone for Horizon Pharma as we expand our business globally.” He continued, “With this approval, we will now focus on developing country-by-country plans to make RAVICTI available to people with urea cycle disorders throughout Europe.”

According to TipRanks’ statistics, out of 7 analysts who have rated HPZN in the last 3 months, 6 gave a Buy rating while 1 remains on the sidelines. The average 12-month price target for the stock is $38.60, marking a 77% upside from where shares last closed. HZNP Consensus

Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) is down close to 2% today following news that Muriolo Ferreria quit as the chairman of the board for Petreolo Braileiro. Ferreria currently serves as the CEO of Vale SA, the world’s leading iron ore producer. Ferreria did not provide the reasoning for his decision. It is reported that in August , Ferreria voted against the sale of a stake in PBR’s fuel distribution list, which led to difficulties with management.  His resignation comes amidst corruption scandals involving PBR’s senior figures in Brazil, as well as the company’s desire to cut back on productivity following falling oil prices. Since September 14, the former chairman has been on a leave of absence due to personal reasons and was replaced by Nelson Carvallo, a fellow board member. The company indicated in a securities filing that Carvahlo would continue to fill in for Ferreria until the next board meeting, although no date was given.

According to TipRanks’ statistics, out of 4 analysts who have rated PBR in the last 3 months, 2 gave a Buy rating and 2 gave a Sell rating. The average 12-month price target for the stock is $5.70, marking a 16% upside from where shares last closed.PBR Consensus

Macrocure Ltd (NASDAQ:MCUR) dropped 15% this morning in pre-market trading after news of changes in senior management. Tomer Kariv, who serves as the director of the company’s board and also the current CEO of Pontifax, will replace David Ben-Ami, the current chairman of the board. Ben-Ami will still serve as a member of the board. CFO Mark Page announced his resignation, to occur in February 2016, to pursue other options. Taking on his responsibilities is Shai Lankry, the current VP of Finance and former CFO of Macrocure.  The company’s Chief Medical Officer Dr. Michal Molyneaux will also resign in December.

CEO Nissim Machiach states, “On behalf of the Board, we would like to profoundly thank David, Mark and Mike for their leadership and contributions to Macrocure. Finally, we are grateful to Tomer for assuming the Chairman role and to David for his continuing Board participation while the Company continues to explore potential strategic alternatives. The Company is in process of selecting and appointing an outside advisory firm to assist with this review.”